An official regulatory nod to cancer concerns could be devastating to Monsanto's bottom line, not to mention it's planned $66 billion mergerwith Bayer AG, as well as to other agrichemical companies that sell glyphosate products.
Ukulawulwa okusemthethweni kokukhathazeka ngomdlavuza kungalimaza umugqa ophansi weMonsanto, ingasaphathwa eyokuthi kuhlelwe ukuhlangana kwama- $ 66 billion neBayer AG, kanye nezinye izinkampani zezolimo ezithengisa imikhiqizo ye-glyphosate.